Egis says Russia removes 11 of its drugs from state subsidies
Egis Nyrt, eastern Europe's fifth-biggest drugmaker, said Russia removed 11 of the company's drugs from its state reimbursement list. The products removed brought about $4 million in sales during the fiscal year ended September 30, Egis said in a statement to the Budapest Stock Exchange (BÉT) after the market close in Budapest yesterday. Egis, based in Budapest, still has 27 products on the list, the statement said. Reimbursements contributed $5 million to Egis's revenue in the three months ended June 30, according to Egis's financial statement. Egis's shares have fallen 10.8% since yesterday, when the Hungarian government unveiled a draft law that will impose new duties on drugmakers. The shares fell 2.9% to Ft 27,000 yesterday. The Budapest-based company has outperformed Hungary's benchmark BUX index by 42% over the past 12 months. (Bloomberg)
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.